IDEAYA Biosciences (IDYA) vs Viking Therapeutics (VKTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
IDEAYA Biosciences (IDYA) has outperformed Viking Therapeutics (VKTX) over the past year, gaining 34.4% versus a loss of 14.3%. Over five years, VKTX leads with a +361.4% price change compared with +55.9% for IDYA. Viking Therapeutics is the larger company by market cap ($3.64 billion vs $3.50 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IDYA | VKTX |
|---|---|---|
| Share price | $36.26 | $28.60 |
| Market cap | $3.50B | $3.64B |
| 1-day change | +0.55% | +3.14% |
| YTD return | +4.31% | -21.18% |
| 1-year return | +34.35% | -14.33% |
| 5-year return | +55.90% | +361.40% |
| EPS (TTM) | $-1.94 | $-4.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $218.71M | $0 |
| Revenue growth (YoY) | +3024.43% | — |
| Net income (latest FY) | $-113.70M | $-359.64M |
| Operating margin | -72.84% | — |
| Net margin | -51.99% | — |
| 52-week high | $42.68 | $43.15 |
| 52-week low | $26.05 | $25.77 |
| Distance from 52-week high | -15.04% | -33.72% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +45.48% | +231.15% |
| Average volume | 779.15K | 4.13M |
| Shares outstanding | 96.49M | 127.17M |
| Employees | 145 | 65 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IDYA has outperformed VKTX by 48.7 percentage points over the past year.
About IDEAYA Biosciences
IDYA stock →IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings.
Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees
About Viking Therapeutics
VKTX stock →Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
IDYA vs VKTX FAQ
Which is bigger, IDEAYA Biosciences or Viking Therapeutics?
Viking Therapeutics (VKTX) is larger, with a market capitalization of $3.64B compared with $3.50B for IDEAYA Biosciences (IDYA).
Which stock has performed better over the past year, IDYA or VKTX?
IDYA returned +34.35% over the past 12 months, compared with -14.33% for VKTX (price return, excluding dividends). Past performance does not predict future results.
Are IDEAYA Biosciences and Viking Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.